[PDF] Top 20 Mutational processes contributing to the development of multiple myeloma.

... correlate mutational processes with gene expression, RNAseq data were normalized to FPKM 11 ...of mutational contribution from each COSMIC signature between transcribed and non-transcribed ... See full document

... As stated before, CRBN protein has been identified as the pharmacological target for thalidomide and its analogs, and there is a clear relationship between low CRBN expres- sion and the resistance to these drugs in ... See full document

... of multiple myeloma, it remains an incurable disease, with relapses and resistances frequently ...on myeloma cells and, to a lower extent, on selected leukocyte subsets such as natural killer ...to ... See full document

... Results: The median age was 53 years with a male/female sex ratio of 34:8. Twenty-six patients had EP disease at the time of diagnosis, and 16 patients developed EP during the course of the disease. We found that the ... See full document

... Multiple myeloma (MM) is a malignancy of clonal plasma cells characterized by the presence of paraproteinemia, destructive bone disease, hypercalcemia, renal failure, and/or hematologic dysfunction 1 ...of ... See full document

... the myeloma cell lines as well as the patient specimens of multiple myeloma are characterized by neoplastic plasma cells that expressed the Syndecan-1 (CD138) cell surface antigen (Kuehl and ...the ... See full document

... the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) ... See full document

... the number of samples used in these studies is often small (typically data from only one to three patients is shown), and the methodologies used (often flow cytometry or immuno- fluorescence) are typically unable to ... See full document

... In conclusion, we have demonstrated here that can- cer-testis antigen SLLP1 shows a tumor-restricted expression pattern and is present in the tumor cells of a substantial proportion of patients with MM. The expres- sion ... See full document

... for multiple myeloma consisted of either single agent or combination regimens of chemotherapy drugs such as melphalan, doxorubicin and vincristine, and the glucocorticosteroids prednisone and dexamethasone ... See full document

... This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate ... See full document

... Multiple myeloma, a cancer of plasma cells, is associated with excessive tumor-induced, osteoclast-mediated bone ...of myeloma in patients, and excessive osteolysis plays a major contributory role in ... See full document

... Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, ... See full document

... Multiple myeloma (MM) is one type of plasma cell malignancy which is characterized by so- called CRAB criteria (hypercalcemia, renal fail- ure, anemia and bony lesions) ...smoldering multiple ... See full document

... of multiple myeloma and its treatment has resulted in a more tailored approach to patient management, with different therapeutics regimens for different patient ...of myeloma patients in whom ... See full document

... in myeloma initiation and ...of multiple myeloma fol- lowing at least two prior lines of ...RR multiple myeloma, panobinostat in combination with steroids and a proteasome inhibitor is ... See full document

... diagnosed multiple myeloma, based on paraprotein in serum or urine, bone marrow clonal plasma cells or plasmacytoma, and myeloma­related symptoms or organ or tissue impair­ ...for myeloma (excluding ... See full document

... possess multiple roles: they are accumulated in BM microenvironment as an initial host response, with potential tumorcidial ...means, myeloma cells secrete attractants for MCs, but in turn, they secrete ... See full document

... tumor mutational profile R based on these final weights is determined as described ...tumor mutational profile with the original input tumor profile and is called using ... See full document

... promote myeloma cell growth and ...between myeloma cells and their adhesion to bone marrow stromal cells (BMSCs) and can activate ERK1/2, STAT3, and AKT pathways to promote survival [13, ... See full document